Weekly Roundup: Enrolment completed and conference top tips and takeaways
Gesynta Pharma completes enrolment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care for women with endometriosis, announced that it has completed enrolment in NOVA, its Phase 2 clinical proof-of-concept and dose-finding trial. A total […]
